Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acid-inhibitory effect of vonoprazan in erosive esophagitis (Four-Day Bravo pH monitoring)
ChiCTR2100041691Phase 4Recruiting
- Sponsor
- Union Hospital
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vonoprazan in erosive esophagitis (EE), sponsored by Union Hospital. Primary endpoint: the percentage of time with esophageal pH less than 4 (%pH<4). Started Feb 2021; status: recruiting.
02
Drugs
vonoprazan
03
Conditions
erosive esophagitis (EE)
Beyond the preview
Go deeper on ChiCTR2100041691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041691.